Effect of aprepitant on intravenous tacrolimus disposition in reduced intensity hematopoietic stem cell transplantation.
Effect of aprepitant on intravenous tacrolimus disposition in reduced intensity hematopoietic stem cell transplantation.
复制标题
DOI：
10.1177/1078155208089846
复制
发表时间：
2008-09-01
期刊：
影响因子：
--
通讯作者：
Edwards, David J
中科院分区：
文献类型：
--
作者：
Ibrahim, Rami B;Abidi, Muneer H;Edwards, David J
AP是一种已知的细胞色素P450 3A4抑制剂，可能影响他克莫司的代谢。我们回顾了2005年9月至2006年9月期间26例低强度移植患者口服AP对静脉注射他克莫司浓度的影响。移植+1天口服AP 125 mg，+2、+3天口服AP 80 mg。他克莫司0.03 mg/kg/d，于移植前6天至移植前1天、移植期间(移植前2天至移植后7天)、移植后+8天持续静脉滴注。他克莫司剂量调整为5~20 ng/mL。他克莫司在AP前、AP中和AP后的剂量校正浓度分别为8.12(95%CI：7.3~9.1)、11.63(95%CI：9.63~13.63)和11.42(95%CI：8.12~14.7)(P
Aprepitant (AP) is a known inhibitor of cytochrome P450 3A4 which may affect tacrolimus metabolism. We retrospectively examined the effect of oral AP on intravenous tacrolimus concentrations in 26 patients undergoing reduced intensity transplantation from 09/2005 to 09/2006. Oral AP 125 mg daily was administered on transplant day +1 and 80 mg on days +2 and +3. Intravenous tacrolimus was administered as a 0.03 mg/kg/day continuous infusion on day -6 through day +1 (pre-AP), during-AP (days +2 to +7), and post-AP starting on day +8. Tacrolimus doses were adjusted to achieve concentrations of 5-20 ng/mL. Dose-corrected tacrolimus concentrations (ng/mL/mg per dose) in the pre-AP, during-AP, and post-AP time periods were: 8.12 (95% CI: 7.3-9.1), 11.63 (95% CI: 9.63-13.63), and 11.42 (95% CI: 8.12-14.7), respectively (P